Clinical trials: ESCC, active
Esophageal Squamous Carcinoma
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT07490002
- Testing
- Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Volunteers
- 33 people
- Sponsor
- Changhai Hospital
ESCC, TAS 102
TAS-102 Plus Radiotherapy in Elderly ESCC
This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.
- Conditions
- ESCC, TAS 102, Radiotherapy
- Trial name
- NCT07196345
- Testing
- TAS-102, Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Qianfoshan Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
SUMMARY Rationale: Esophageal cancer (EC) is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide.
- Trial name
- ESCALATE (NCT07359417)
- Testing
- Radiation: MRI guided radiotherapy
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University
Esophageal Cancer
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06663059
- Testing
- Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle, Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
This study is a single-arm clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy in the first-line treatment of patients with recurrent or metastatic esophageal squamous…
- Trial name
- NCT07290010
- Testing
- Iparomlimab and Tuvonralimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced…
- Trial name
- KUNLUN (NCT04550260)
- Testing
- Durvalumab, cisplatin + fluorouracil, cisplatin + capecitabine
- Where
- 133 sites in United States, Belgium and 14 more
- Volunteers
- 640 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
This study is a prospective, single-arm, single-center Phase Ib clinical trial of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07697040
- Testing
- Becotatug Vedotin Combined with Cisplatin and Concurrent Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
O-GlcNAcylation Induced HMGB1 Signalling
This study investigates how HMGB1 compartmentalisation and O-GlcNAcylation regulate inflammatory signalling, autophagy, and immune escape in cancer.
- Trial name
- NCT07702253
- Testing
- specimen collection
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant…
- Trial name
- TD-NEOE3V3 (NCT06952621)
- Testing
- 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Tang-Du Hospital
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line…
- Trial name
- NCT07733180
- Testing
- Tislelizumab, Oxaliplatin, Leucovorin
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
ESCC
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received…
- Trial name
- NCT07524374
- Testing
- SHR-1701+ liposomal irinotecan (II)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhigang Li
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal…
- Trial name
- NEOCRTEC2501 (NCT07638436)
- Testing
- Adebrelimab Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
The aim of this study is to compare the efficacy and safety of liposome irinotecan +5-FU and irinotecan / irinotecan +5-FU regimens in the second-line treatment of esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06501664
- Testing
- liposomal irinotecan, 5-FU, LV
- Volunteers
- 360 people
- Sponsor
- Rui-hua Xu, MD, PhD
Esophageal Cancer
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
- Trial name
- NCT05182944
- Testing
- A：non-pCR patients, B：non-pCR patients, A：pCR patients
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University